Ask AI
ProCE Banner Activity

Expert Guidance on Non-Factor Approaches to Managing Hemophilia

Clinical Thought

Explore expert-described management approaches for several patient case scenarios and get insights into questions posed by a healthcare professional audience during a live symposium held adjacent to the American Society of Hematology Annual Meeting 2025.

Released: December 31, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Target Audience

This activity has been designed to meet the educational needs of hematologists and other healthcare professionals who manage patients with hemophilia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop individualized prophylaxis management strategies for patients with moderate to severe hemophilia based on current evidence for new and emerging treatments

  • Apply efficacy and safety data for current and emerging non-factor replacement therapies in moderate to severe hemophilia to clinical practice

Disclosure

Primary Author

Stacy E. Croteau, MD, MMS: consultant/advisor/speaker: Biomarin, Pfizer, Sanofi; researcher: Genentech, Sanofi, Spark Therapeutics.

Kristin N. Maher, MD, PhD: researcher: Genentech.

Steven Pipe, MD: consultant/advisor/speaker: Bayer, BioMarin, CSL Behring, HEMA Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Poseida, Roche/Genentech, Sanofi, Spark, Takeda; researcher: Siemens, YewSavin; scientific advisory board member: Equilibra Bioscience, GeneVentiv.